Shareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.

Deciphera Pharmaceuticals Delist

Deciphera Pharmaceuticals




MILWAUKEE, April 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Deciphera (NASDAQ: DCPH) for possible breaches of fiduciary duty and other violations of law in its transaction with ONO.

AdemiLogo (PRNewsfoto/Ademi LLP)

Click here to learn how to join the or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, Deciphera stockholders will receive only $25.60 per share in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO, for a total equity value of $2.4 billion. The transaction agreement unreasonably limits competing transactions for Deciphera by imposing a significant penalty if Deciphera accepts a competing bid. Deciphera insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Deciphera's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Deciphera common stock and wish to obtain additional information, please contact Guri Ademi either at or toll-free: 866-264-3995, or                      

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.


Ademi LLP                                                                  

Guri Ademi

Toll Free: (866) 264-3995

Fax: (414) 482-8001

Cision View original content to download multimedia:


Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via